FDA Approves Kite Pharma’s Cancer Drug Yescarta

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

FDA Approves Kite Pharma’s Cancer Drug Yescarta
Photo by Drew Hays on Unsplash

Santa Monica-based Kite Pharma, a subsidiary of biopharma giant Gilead Sciences, announced on Friday that it has received approval from the Food and Drug Administration for a new immunotherapy drug that can be used in the early-stage treatment of certain cancers.


Yescarta, an intravenous CAR-T cell treatment that aims to bolster the immune system to fight cancer cells, is the first therapeutic of its kind to receive FDA approval for the early treatment of large B-cell lymphoma—a type of non-Hodgkin lymphoma—that has either relapsed or can’t be addressed with other cancer treatments like chemoimmunotherapy.

Most CAR-T cell therapies are reserved as a last resort for cancer patients who have exhausted all other options. At that point, however, their immune systems may be too weak to effectively utilize the therapeutic. While most clinical CAR-T cell trials involve patients who are at an advanced stage in their cancer treatments, Yescarta’s clinical trial was filled with patients who used the drug as a second- or third-resort.

CAR-T cell therapies have taken the oncology world by storm as a promising, potentially less invasive route for treating cancers, with many local biotech firms making moves in the space. In January, West Hills-based ImmPACT Bio raised $111 million to further its work of reengineering patients’ cells to boost the immune system. Culver City-based Appia Bio, meanwhile, emerged from stealth last spring to create off-the-shelf cell therapies that can be delivered quicker and cheaper to patients, and inked a deal with Kite Pharma last August to develop CAR-T cell treatments.

Kite Pharma has focused almost exclusively on CAR-T cell therapies since it was founded in 2009. Gilead Sciences acquired Kite for $11.9 billion in 2017.

“Kite started with a very bold goal: creating the hope of survival through cell therapy,” Kite CEO Christi Shaw said in a statement. “Today’s FDA approval brings that hope to more patients by enabling the power of CAR-T cell therapy to be used earlier in the treatment journey. This milestone has been years in the making.”

https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

Cadence

How Real-Time Data Is Helping Physicians Track Their Patients, One Heartbeat at a Time

S.C. Stuart
S.C. Stuart is a foreign correspondent (ELLE China, Esquire Latin America), Contributing Writer at Ziff Davis PCMag, and consults as a futurist for Hollywood Studios. Previously, S.C. was the head of digital at Hearst Magazines International while serving as a Non-Executive Director, UK Trade & Investment (US) and Digital Advisor at The Smithsonian.
How Real-Time Data Is Helping Physicians Track Their Patients, One Heartbeat at a Time

Are you a human node on a health-based digital network?

According to research from Insider Intelligence, the U.S. smart wearable user market is poised to grow 25.5% in 2023. Which is to say, there are an increasing number of Angelenos walking around this city whose vital signs can be tracked day and night via their doctor's digital device. If you've signed up to a health-based portal via a workplace insurance scheme, or through a primary care provider's portal which utilizes Google Fit, you’re one of them.

Do you know your baseline health status and resting heartbeat? Can you track your pulse, and take your own blood pressure? Have you received genetic counseling based on the sequencing of your genome? Do you avoid dairy because it bloats, or because you know you possess the variant that indicates lactose intolerance?

Read moreShow less

Who Will Win LA's E-scooter Wars?

Maylin Tu
Maylin Tu is a freelance writer who lives in L.A. She writes about scooters, bikes and micro-mobility. Find her hovering by the cheese at your next local tech mixer.
Who Will Win LA's E-scooter Wars?
Evan Xie

Los Angeles — it’s not just beautiful weather, traffic and the Hollywood Walk of Fame — it’s also the largest shared micromobility market in the U.S. with six operators permitted to deploy up to 6,000 vehicles each.

And despite the open market policy, the competition shows no signs of slowing down.

Read moreShow less

March Capital Raises $650 Million Fund to Invest in AI Startups

Samson Amore

Samson Amore is a reporter for dot.LA. He holds a degree in journalism from Emerson College and previously covered technology and entertainment for TheWrap and reported on the SoCal startup scene for the Los Angeles Business Journal. Send tips or pitches to samsonamore@dot.la and find him on Twitter @Samsonamore.

March Capital Raises $650 Million Fund to Invest in AI Startups
March Capital founder Jamie Montgomery. Illustration by Dilara Mundy.

Santa Monica-based venture outfit March Capital announced Feb. 3 that it raised its largest fund to date, a $650 million investment vehicle that will be used to back up to 15 startups focused on delivering new uses of artificial intelligence.

Read moreShow less
https://twitter.com/samsonamore
samsonamore@dot.la
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending